Shuyu Chu

Shuyu Chu

Auto-generated profile, based on publicly available information

Shuyu Chu

Global Biometrics and Data Sciences, Bristol Myers Squibb, Princeton, NJ

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2015 in Nature Geoscience
Verified
Journal Article
Closed access
PDF file
EGEsteban Gazel
Esteban Gazel
JHJorden L. Hayes
Jorden L. Hayes
KHKaj Hoernle
Kaj Hoernle
PKPeter Kelemen
Peter Kelemen
EEErik Everson
Erik Everson
GYGene M. Yogodzinski
Gene M. Yogodzinski

1 November 2017 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
JBJohn S. Brownstein
John S. Brownstein
SCShuyu Chu
Shuyu Chu
AMAchla Marathe
Achla Marathe
MMMadhav V Marathe
Madhav V Marathe
ANAndre T Nguyen
Andre T Nguyen
QZQian Zhang
Qian Zhang
A multidisciplinary journal that focuses on public health and technology, public health informatics, mass media campaigns, surveillance, and innovation in public health practice and research. Also dedicated to rapid open data sharing during epidemics.

10 December 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
YCYiming Cheng
Yiming Cheng
SCShuyu Chu
Shuyu Chu
JPJie Pu
Jie Pu
MCMin Chen
Min Chen
KHKevin Hong
Kevin Hong
YLYan Li
Yan Li
PURPOSE: The advent of new therapeutic modalities highlighted deficiencies in the traditional maximum tolerated dose approach for oncology drug dose selection and prompted the Food and Drug Administration (FDA)'s Project Optimus initiative, which suggests that sponsors take a holistic approach, including efficacy, safety, and pharmacokinetic (PK) and pharmacodynamic data, in conjunction with integrated exposure-response (ER) analyses. However, this method comes with an inherent challenge of the collation of the multisource data. To address this issue, an ER-based clinical utility score (CUS) framework, combining benefit and risk into a single measurement, was developed. METHODS: Model-predicted outcomes for each clinically relevant end point, informed by ER modeling, are converted to a CUS using a user-defined utility function. Thereafter, individual CUS is integrated into a single score with user-defined weighting for each end point. The user-defined weighting feature allows the user to incorporate expert knowledge/understanding into weighing the product's benefit versus risk profile. RESULTS: To validate the framework, data were leveraged from over 50 oncology programs from 2019 to 2023 on the basis of FDA new drug application/biologics license application review packages and/or related literature studies. Five representative cases were selected for in-depth evaluation. Results showed that the optimal benefit-risk ratio (highest CUS) was consistently observed at PK exposures synonymous with recommended doses. A recurring theme across cases was a greater emphasis on safety over efficacy in oncology drug dose determination. CONCLUSION: The ER-based CUS framework offers a strategic tool to navigate the complexities of dose selection in oncology programs. It serves as a pillar to the importance of integrative data analysis, aligning with the vision of Project Optimus , and demonstrates its potential in guiding dose optimization by balancing therapeutic benefits against risk.